OA11875A - 1-Amino triazolo Ä4,3-aÜquinazoline-5-ones et/ou- 5-thiones inhibitrices de phosphodiesterases IV. - Google Patents

1-Amino triazolo Ä4,3-aÜquinazoline-5-ones et/ou- 5-thiones inhibitrices de phosphodiesterases IV. Download PDF

Info

Publication number
OA11875A
OA11875A OA1200100282A OA1200100282A OA11875A OA 11875 A OA11875 A OA 11875A OA 1200100282 A OA1200100282 A OA 1200100282A OA 1200100282 A OA1200100282 A OA 1200100282A OA 11875 A OA11875 A OA 11875A
Authority
OA
OAPI
Prior art keywords
triazolo
quinazolin
bromo
pyrrolidin
azepan
Prior art date
Application number
OA1200100282A
Other languages
English (en)
French (fr)
Inventor
Charles Andrianjara
Francine Breuzard
Bernard Gaudilliere
Remi Lavalette
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of OA11875A publication Critical patent/OA11875A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
OA1200100282A 1999-04-28 2000-04-28 1-Amino triazolo Ä4,3-aÜquinazoline-5-ones et/ou- 5-thiones inhibitrices de phosphodiesterases IV. OA11875A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9905398A FR2792938B1 (fr) 1999-04-28 1999-04-28 NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV

Publications (1)

Publication Number Publication Date
OA11875A true OA11875A (en) 2006-03-29

Family

ID=9544983

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100282A OA11875A (en) 1999-04-28 2000-04-28 1-Amino triazolo Ä4,3-aÜquinazoline-5-ones et/ou- 5-thiones inhibitrices de phosphodiesterases IV.

Country Status (34)

Country Link
US (1) US6828315B1 (sk)
EP (1) EP1177195B1 (sk)
JP (1) JP2002543199A (sk)
KR (1) KR20020008166A (sk)
CN (1) CN1352644A (sk)
AP (1) AP2001002309A0 (sk)
AT (1) ATE234840T1 (sk)
AU (1) AU4411500A (sk)
BG (1) BG106026A (sk)
BR (1) BR0010072A (sk)
CA (1) CA2388658A1 (sk)
DE (1) DE60001735T2 (sk)
DK (1) DK1177195T3 (sk)
DZ (1) DZ3154A1 (sk)
EA (1) EA004373B1 (sk)
EE (1) EE200100566A (sk)
ES (1) ES2194779T3 (sk)
FR (1) FR2792938B1 (sk)
HK (1) HK1044938B (sk)
HR (1) HRP20010794B1 (sk)
HU (1) HUP0202656A3 (sk)
IL (1) IL146178A0 (sk)
IS (1) IS6114A (sk)
MA (1) MA27343A1 (sk)
MX (1) MXPA01010888A (sk)
NO (1) NO20015235L (sk)
OA (1) OA11875A (sk)
PL (1) PL351951A1 (sk)
PT (1) PT1177195E (sk)
SK (1) SK15322001A3 (sk)
TR (1) TR200103099T2 (sk)
WO (1) WO2000066584A1 (sk)
YU (1) YU76401A (sk)
ZA (1) ZA200108847B (sk)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
PA8539501A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US20040146561A1 (en) * 2001-05-23 2004-07-29 Naoki Sakurai Compositions for promoting healing of bone fracture
EP1285922A1 (en) * 2001-08-13 2003-02-26 Warner-Lambert Company 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
FR2832711B1 (fr) 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
CN100572381C (zh) * 2002-11-06 2009-12-23 Aska制药株式会社 吡唑并二氮杂萘衍生物
RU2328499C2 (ru) 2003-01-09 2008-07-10 Астеллас Фарма Инк. Производные пирролопиридазина, фармацевтическая композиция, способ профилактики или лечения заболеваний, применение в качестве ингибитора фосфодиэстеразы iv, и/или продуцирования tnf
JP2007533760A (ja) * 2004-04-23 2007-11-22 セルジーン・コーポレーション 肺高血圧症を治療し管理するための、pde4モジュレーターの使用方法及びpde4モジュレーターを含む組成物
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008041118A2 (en) 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
WO2009013286A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Organic compounds
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
CN103224498B (zh) * 2013-05-07 2015-10-28 陈定奔 两种唑并喹唑啉酮稠杂环的新合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865824A (en) * 1972-03-07 1975-02-11 Icn Pharmaceuticals 2-Aryl-7-substituted pyrazolo {8 1,5{i a{b {9 1,3,5-triazines
US3850932A (en) * 1973-06-28 1974-11-26 Sandoz Ag 5-(2-carboxy and 2-carboalkoxy-phenylamino)-1,2,4-triazolo-quinazolines
IL66835A (en) * 1981-09-24 1988-05-31 Roussel Uclaf 1,4-disubstituted(1,2,4)triazolo(4,3-alpha)quinazolin-5(4h)-one derivatives and their salts,their preparation and pharmaceutical compositions containing them
JPS6028979A (ja) * 1983-07-14 1985-02-14 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン類化合物
SK282167B6 (sk) * 1995-06-06 2001-11-06 Pfizer Inc. Tricyklické 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a] pyridíny a farmaceutický prostriedok na ich báze
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.

Also Published As

Publication number Publication date
MA27343A1 (fr) 2005-06-01
SK15322001A3 (sk) 2002-11-06
EP1177195A1 (fr) 2002-02-06
WO2000066584B1 (fr) 2001-02-15
AU4411500A (en) 2000-11-17
EA004373B1 (ru) 2004-04-29
BG106026A (bg) 2002-05-31
HUP0202656A2 (hu) 2002-12-28
ES2194779T3 (es) 2003-12-01
DE60001735D1 (de) 2003-04-24
KR20020008166A (ko) 2002-01-29
HRP20010794A2 (en) 2003-04-30
NO20015235L (no) 2001-12-21
NO20015235D0 (no) 2001-10-26
HK1044938A1 (en) 2002-11-08
DZ3154A1 (fr) 2000-11-09
HRP20010794B1 (en) 2004-06-30
FR2792938B1 (fr) 2001-07-06
CA2388658A1 (en) 2000-11-09
JP2002543199A (ja) 2002-12-17
HUP0202656A3 (en) 2004-12-28
AP2001002309A0 (en) 2001-12-31
TR200103099T2 (tr) 2002-12-23
IL146178A0 (en) 2002-07-25
WO2000066584A1 (fr) 2000-11-09
CN1352644A (zh) 2002-06-05
BR0010072A (pt) 2002-02-05
PT1177195E (pt) 2003-07-31
IS6114A (is) 2001-10-19
DK1177195T3 (da) 2003-07-14
EP1177195B1 (fr) 2003-03-19
ATE234840T1 (de) 2003-04-15
FR2792938A1 (fr) 2000-11-03
YU76401A (sh) 2004-07-15
EA200100994A1 (ru) 2002-06-27
HK1044938B (zh) 2003-12-24
PL351951A1 (en) 2003-07-14
ZA200108847B (en) 2002-11-27
US6828315B1 (en) 2004-12-07
EE200100566A (et) 2003-02-17
DE60001735T2 (de) 2004-02-05
MXPA01010888A (es) 2003-06-24

Similar Documents

Publication Publication Date Title
EP1177195B1 (fr) 1-AMINO TRIAZOLO 4,3-a! QUINAZOLINE-5-ONES ET/OU -5-THIONES INHIBITRICES DE PHOSPHODIESTERASES IV
US6747035B2 (en) 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
EP1086105B1 (en) Fused azepinone cyclin dependent kinase inhibitors
US5840895A (en) Triazole intermediates for tricyclic benzazepine and benzothiazepine derivatives
JP2005529843A (ja) トリアゾロ[4,3−a]ピリド[2,3−d]ピリミジン−5−オン、それらを含有する組成物、その製造方法及び使用
EP1556382B1 (fr) Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique.
TW201300390A (zh) 喹□啉化合物
EP1590355A1 (fr) Derives d azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR100845749B1 (ko) 트리시클, 이의 제조 및 약학적 제제로서의 용도
Nguyen et al. Synthesis, in vitro α-glucosidase, and acetylcholinesterase inhibitory activities of novel indol-fused pyrano [2, 3-d] pyrimidine compounds
EP1092715B1 (fr) Composés cyano-indoles inhibiteurs de recapture de sérotonine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
CZ20022222A3 (cs) Nové substituované pyrazolo [4,3-e] diazepiny, farmaceutické kompozice obsahující tyto diazepiny, jejich použití jako léčiva a způsoby jejich přípravy
FR2704547A1 (fr) Nouveaux composés pyrrolopyraziniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
JP2001512124A (ja) 新規な2,3−ベンゾジアゼピン誘導体
HUT63423A (en) Process for producing tetracyclic diimidazo- and imidazopyrimido quinazoline derivatives and pharmaceutical compositions comprising same
US6962912B2 (en) Substituted pyrazolo[4,3-e]diazepines, pharmaceutical compositions containing them, use as medicinal products and processes for preparing them
LU84775A1 (fr) Nouveaux derives cycloaliphatiques condenses de pyrido(1,2-a)pyrimidines substituees